Biocartis CEO steps down, company announces strong 2016 results

March 2, 2017 News BioVox

In a press release stating strong annual results for the cancer diagnostic producer, Biocartis also announced a change in its top management position. Its current CEO, Rudi Pauwels, has expressed his preference to focus on the longer term strategy of Biocartis, including a pathway towards a Next-Generation Sequencing based product offering. Pauwels will act as chairman of a new strategy committee of the Board. Hilde Windels, currently Deputy CEO, will assume the role of CEO until a successor is on board.

According to the numbers, Biocartis is in excellent shape. While hoping to install 175 new Idylla instruments in 2016, the company was easily able to beat its goal, installing 224 new consoles. Biocartis also sold 7.5 times more diagnostic cartridges compared to the preceding year.

In the meantime the company keeps on releasing new diagnostic cartridges. Biocartis announced the launch of its third liquid biopsy test, the ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO) for metastatic colorectal cancer, developed in collaboration with Merck. The company now has a total of 9 diagnostic tests for its Idylla platform on the market.

More news on Biocartis


Avatar photo
BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter